Ozempic and Mounjaro are both weekly injections approved for type 2 diabetes, but they are different drugs: Ozempic is semaglutide and Mounjaro is tirzepatide. Here is a neutral rundown. This is educational, not medical advice.
| Ozempic | Mounjaro | |
|---|---|---|
| Active drug | Semaglutide | Tirzepatide |
| How it works | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| FDA-approved use | Type 2 diabetes (Ozempic also has a cardiovascular indication) | Type 2 diabetes |
| Standard max dose | 2 mg weekly | 15 mg weekly |
| Form | Multi-dose weekly pen | Weekly pen or vial |
Ozempic and Mounjaro are the diabetes brands. The same two molecules are sold under different names for weight management: semaglutide as Wegovy and tirzepatide as Zepbound. That is why you cannot simply swap between labels — the approvals, doses and pens differ.
Both lower blood sugar and often support weight loss; tirzepatide’s dual action produced greater average effects in trials, but responses are individual. Both share GLP-1-style digestive side effects during titration.
No — Ozempic is semaglutide and Mounjaro is tirzepatide. Both treat type 2 diabetes, but they are different molecules.
In trials, tirzepatide (Mounjaro) produced greater average reductions in blood sugar and weight than semaglutide (Ozempic). Individual results vary.
Same molecules, different brands: Wegovy is semaglutide for weight management, and Zepbound is tirzepatide for weight management.
Ozempic goes to 2 mg weekly and Mounjaro to 15 mg weekly on the standard schedules.
No — they are different drugs with different dosing. Any change is a decision for your prescriber.